Lupin breaks into Dow Jones sustainability indices after scoring 91/100 in global ESG assessment

Pharmaceutical major Lupin has entered the Dow Jones Best-in-Class (DJBIC) Indices for the first time, following a high sustainability assessment score that placed it among the top-ranked global drugmakers on environmental, social and governance (ESG) parameters.

The Mumbai-headquartered company said it has been included in both the DJBIC World Index and the DJBIC Emerging Markets Index for 2026 after securing a score of 91 out of 100 in the S&P Global Corporate Sustainability Assessment (CSA) 2025. The score placed Lupin among the top 1% companies globally within the pharmaceutical sector.

The development comes amid growing investor focus on ESG-linked metrics across industries, particularly in pharmaceuticals, where supply-chain transparency, manufacturing practices and governance standards are increasingly influencing procurement and capital allocation decisions.

Global sustainability benchmarks tighten scrutiny

The Dow Jones Best-in-Class World Index tracks the top 10% of 2,500 companies in the S&P Global Broad Market Index based on sustainability performance, while the Emerging Markets benchmark evaluates the top-performing companies among 800 firms across developing economies.

Inclusion in such indices has become a closely watched indicator among institutional investors and ESG-focused funds, especially as companies face increasing disclosure requirements around emissions, labour standards and governance practices.

Indian pharmaceutical companies, many of which derive a significant share of revenues from overseas markets, have also stepped up sustainability reporting and compliance initiatives in recent years amid tighter global scrutiny.

Commenting on the development, Ramesh Swaminathan, Executive Director and Global CFO at Lupin, stated that the inclusion reflected the company’s governance standards and long-term sustainability agenda centred around responsible growth and operational resilience.

ESG gains prominence in pharma sector

Lupin said its sustainability initiatives include science-based environmental targets, responsible supply-chain practices and workplace inclusion measures. The company operates across more than 100 markets and has 15 manufacturing facilities and seven research centres globally.

According to the company, the assessment also evaluated governance frameworks and operational resilience — areas that have become increasingly important for investors after multiple compliance-related disruptions in the global pharmaceutical industry over the past decade.

The Dow Jones sustainability indices are based on assessments conducted by S&P Global Sustainable and are tracked by a range of global asset managers and sustainability-linked investment products.